perphenazine has been researched along with Psychoses in 103 studies
Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.
perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to compare serum amino acid patterns in patients on long-term clozapine treatment with long-term conventional antipsychotic treatment, and their relationships to insulin resistance and antipsychotic serum concentrations." | 7.81 | Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. ( Hall, K; Lewitt, M; Melkersson, K, 2015) |
| "A 50-year old woman developed symptoms of a neuroleptic malignant syndrome with myoglobinuric renal failure during treatment with perphenazine." | 7.67 | Neuroleptic malignant syndrome during perphenazine treatment. ( Andersen, PT; Aunsholt, NA; Nielsen, D, 1987) |
| "In an investigation of 109 patients on neuroleptics in a vegetable oil base, four of the patients developed abscesses at the site of deposits of perphenazine enantate given intramuscularly in large doses every 1-4 weeks." | 7.66 | Abscesses following prolonged intramuscular administration of perphenazine enantate. ( Forsman, A; Starmark, JE, 1980) |
| " The aim of our study was to assess social cognition in schizophrenia inpatients being treated with first-generation antipsychotic drugs (FGAs), n=28 (perphenazine and haloperidol, FGAs) or with second-generation antipsychotic drugs (SGAs), n=56 (olanzapine and clozapine, SGAs)." | 5.16 | Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs. ( Czernikiewicz, A; Kucharska-Pietura, K; Mortimer, A; Tylec, A, 2012) |
| " In this context we carried out a double-blind study of the therapeutic value of clozapine and perphenazine in acute psychoses of varying symptomatology anc aetiology." | 5.04 | Clozapine versus perphenazine: the value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity. ( Dols, LC; Korf, J; Van Praag, HM, 1976) |
| "The aim of this study was to compare serum amino acid patterns in patients on long-term clozapine treatment with long-term conventional antipsychotic treatment, and their relationships to insulin resistance and antipsychotic serum concentrations." | 3.81 | Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics. ( Hall, K; Lewitt, M; Melkersson, K, 2015) |
| "A 50-year old woman developed symptoms of a neuroleptic malignant syndrome with myoglobinuric renal failure during treatment with perphenazine." | 3.67 | Neuroleptic malignant syndrome during perphenazine treatment. ( Andersen, PT; Aunsholt, NA; Nielsen, D, 1987) |
| "In an investigation of 109 patients on neuroleptics in a vegetable oil base, four of the patients developed abscesses at the site of deposits of perphenazine enantate given intramuscularly in large doses every 1-4 weeks." | 3.66 | Abscesses following prolonged intramuscular administration of perphenazine enantate. ( Forsman, A; Starmark, JE, 1980) |
| "Plasma concentrations of perphenazine (PPZ) (Trilafon) and perphenazinesulphoxide (PPZSO) were estimated during a 2-week period in 16 patients receiving peroral PPZ treatment for various psychotic disorders." | 3.65 | Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. ( Hansen, LB; Larsen, NE, 1977) |
| "Citalopram was found to be more efficacious than placebo in the short-term hospital treatment of psychotic symptoms and behavioral disturbances in nondepressed, demented patients." | 2.70 | Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. ( Bharucha, A; Chew, ML; Huber, KA; Jacob, NJ; Kastango, KB; Marin, R; Mazumdar, S; Mulsant, BH; Pollock, BG; Rosen, J; Sweet, RA, 2002) |
| "Perphenazine level was not correlated with EPS; but benztropine, given only if required for serious EPS, was more likely to be used when perphenazine levels were elevated." | 2.67 | The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects. ( Bowers, MB; Jatlow, PI; Kincare, P; Mazure, CM; Nelson, JC, 1990) |
| " The average daily dosage was 81." | 2.64 | Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial. ( Fensbo, C; Fruensgaard, K; Hansen, KM; Sihm, F; Wollenberg, J, 1978) |
| "Risperidone was well tolerated despite this adolescent's severe cardiac and pulmonary illnesses." | 1.29 | Use of risperidone in psychotic disorder following ischemic brain damage. ( DeMaso, DR; Steingard, RJ; Zimnitzky, BM, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 72 (69.90) | 18.7374 |
| 1990's | 19 (18.45) | 18.2507 |
| 2000's | 6 (5.83) | 29.6817 |
| 2010's | 5 (4.85) | 24.3611 |
| 2020's | 1 (0.97) | 2.80 |
| Authors | Studies |
|---|---|
| Pathak, S | 1 |
| Jiang, Y | 1 |
| DiPetrillo, L | 1 |
| Todtenkopf, MS | 1 |
| Liu, Y | 1 |
| Correll, CU | 1 |
| Bareis, N | 1 |
| Stroup, TS | 1 |
| Melkersson, K | 1 |
| Lewitt, M | 1 |
| Hall, K | 1 |
| Crespo-Facorro, B | 1 |
| Rodríguez-Sánchez, JM | 1 |
| Pérez-Iglesias, R | 1 |
| Mata, I | 1 |
| Ayesa, R | 1 |
| Ramirez-Bonilla, M | 1 |
| Martínez-Garcia, O | 1 |
| Vázquez-Barquero, JL | 1 |
| Abbott, A | 1 |
| Opjordsmoen, S | 1 |
| Melle, I | 1 |
| Friis, S | 1 |
| Haahr, U | 1 |
| Johannessen, JO | 1 |
| Larsen, TK | 1 |
| Rund, BR | 1 |
| Simonsen, E | 1 |
| Vaglum, P | 1 |
| McGlashan, TH | 1 |
| Zedkova, I | 1 |
| Dudova, I | 1 |
| Urbanek, T | 1 |
| Hrdlicka, M | 1 |
| Kucharska-Pietura, K | 1 |
| Mortimer, A | 1 |
| Tylec, A | 1 |
| Czernikiewicz, A | 1 |
| AYD, FJ | 2 |
| CAHN, CH | 1 |
| LEHMANN, HE | 1 |
| O'REILLY, PO | 1 |
| WOJCICKI, HM | 1 |
| HRYCHUK, W | 1 |
| KEOGH, RP | 1 |
| MOHR, H | 1 |
| CALLENS, M | 2 |
| WEISS, II | 1 |
| RUBINGER, JH | 1 |
| SORIN, M | 1 |
| RYZEN, N | 1 |
| SCHOPMANS, A | 1 |
| TEMPEL, H | 1 |
| SCHULSINGER, F | 1 |
| JENSEN, R | 1 |
| ANDERSEN, E | 1 |
| HANSEN, G | 2 |
| COHEN, H | 1 |
| FREIREICH, AZ | 1 |
| DARLING, HF | 1 |
| KOFMAN, O | 1 |
| PENNINGTON, VN | 1 |
| HACKSTEIN, FG | 1 |
| NAHUNEK, K | 3 |
| RODOVA, A | 1 |
| GROSS, H | 1 |
| FRUEHMANN, E | 1 |
| KALTENBAECK, E | 1 |
| OLTMAN, JE | 1 |
| FRIEDMAN, S | 1 |
| HOFF, H | 1 |
| HOFMANN, G | 1 |
| BARBOUR, JP | 1 |
| SOULAIRAC, A | 1 |
| GEIER, S | 1 |
| MOREL, P | 1 |
| FILLIOZAT, AM | 1 |
| FILLIOZAT, R | 1 |
| CHAVANNES, N | 1 |
| RONDEPIERRE, JJ | 1 |
| ROPERT, R | 1 |
| BOEGNER-PLICHET, M | 1 |
| PIRET, J | 1 |
| GARRABE, J | 1 |
| PEYROUZET, JM | 1 |
| ZAHRADNIK, M | 1 |
| BORDELEAU, JM | 1 |
| LAZURE, D | 1 |
| DESROSIERS, M | 1 |
| DOUYON, L | 1 |
| MORIN, L | 1 |
| Ravn, J | 1 |
| Kragh, ER | 1 |
| GROSS, M | 1 |
| HITCHMAN, I | 1 |
| REEVES, WP | 1 |
| LAWRENCE, J | 1 |
| BACON, EF | 1 |
| JENKINS, SB | 1 |
| SAMBORSKI, AH | 1 |
| FORREST, FM | 1 |
| GEITER, CW | 1 |
| SNOW, HL | 1 |
| STEINBACH, M | 1 |
| HUANG, CL | 1 |
| KURLAND, AA | 3 |
| HARDI, I | 1 |
| Faurbye, A | 1 |
| Clausen, J | 1 |
| KRIS, EB | 1 |
| GERST, D | 1 |
| FLEISCHL, H | 1 |
| HARTMAN, BJ | 1 |
| ITIL, TM | 1 |
| MURPHREE, HB | 1 |
| GOLDSTEIN, L | 1 |
| PFEIFFER, CC | 1 |
| SCHRAMM, LP | 1 |
| JENNEY, EH | 1 |
| OESTERLEIN, O | 1 |
| RIED, E | 1 |
| RASMUSSEN, C | 1 |
| Citrome, L | 1 |
| Jaffe, A | 1 |
| Martello, D | 1 |
| Allingham, B | 1 |
| Levine, J | 2 |
| Starmark, JE | 1 |
| Forsman, A | 1 |
| Hansen, LB | 4 |
| Larsen, NE | 4 |
| Hertrich, O | 1 |
| Vestergård, P | 1 |
| Gulmann, N | 1 |
| Hale, MS | 1 |
| Bellizzi, J | 1 |
| Foglia, JP | 1 |
| Sorisio, D | 1 |
| Kirshner, MA | 1 |
| Mulsant, BH | 3 |
| Perel, JM | 1 |
| Caspi, N | 1 |
| Amore, M | 1 |
| Giordani, L | 1 |
| Giorgetti, G | 1 |
| Zazzeri, N | 1 |
| Sweet, RA | 2 |
| Pollock, BG | 2 |
| Rosen, J | 2 |
| Henteleff, RA | 1 |
| Mazure, CM | 7 |
| Quinlan, DM | 1 |
| Bowers, MB | 8 |
| Zimnitzky, BM | 1 |
| DeMaso, DR | 1 |
| Steingard, RJ | 1 |
| Flint, AJ | 1 |
| Rifat, SL | 1 |
| Lauerma, H | 1 |
| Tuliharju, M | 1 |
| Nelson, JC | 6 |
| Jatlow, PI | 7 |
| Cooke, C | 1 |
| de Leon, J | 1 |
| Coley, KC | 1 |
| Carter, CS | 1 |
| DaPos, SV | 1 |
| Maxwell, R | 1 |
| Wilson, JW | 1 |
| Branch, RA | 1 |
| Levkovitz, Y | 1 |
| Bloch, Y | 1 |
| Kaplan, D | 1 |
| Diskin, A | 1 |
| Abramovitchi, I | 1 |
| Baumann, P | 1 |
| Eap, CB | 1 |
| Zullino, DF | 1 |
| Mazumdar, S | 1 |
| Bharucha, A | 1 |
| Marin, R | 1 |
| Jacob, NJ | 1 |
| Huber, KA | 1 |
| Kastango, KB | 1 |
| Chew, ML | 1 |
| Ketai, R | 1 |
| Fruensgaard, K | 2 |
| Wollenberg, J | 1 |
| Hansen, KM | 1 |
| Fensbo, C | 1 |
| Sihm, F | 1 |
| Huapaya, LV | 1 |
| Van Praag, HM | 1 |
| Korf, J | 1 |
| Dols, LC | 1 |
| Swett, C | 1 |
| Silbermann, RM | 1 |
| Beenen, F | 1 |
| de Jong, H | 1 |
| Warkentin, S | 1 |
| Nilsson, A | 1 |
| Karlson, S | 1 |
| Risberg, J | 1 |
| Franze'n, G | 1 |
| Gustafson, L | 1 |
| Kincare, P | 1 |
| Svestka, J | 1 |
| Rysánek, R | 1 |
| Cesková, E | 1 |
| Olesen, OV | 1 |
| Bartels, U | 1 |
| Poulsen, JH | 1 |
| Haffner, F | 1 |
| Coryell, W | 1 |
| Moranville, JT | 1 |
| Swigar, ME | 1 |
| Hoffman, FJ | 1 |
| Nielsen, D | 1 |
| Aunsholt, NA | 1 |
| Andersen, PT | 1 |
| Remvig, J | 1 |
| Larsen, H | 1 |
| Rask, P | 1 |
| Skausig, OB | 1 |
| Skov, S | 1 |
| Strömgren, LS | 1 |
| Pelonero, AL | 1 |
| Levenson, JL | 1 |
| Silverman, JJ | 1 |
| Falk, MA | 1 |
| Lindholm, H | 1 |
| Ljungberg, L | 1 |
| Bakke, O | 1 |
| Fann, WE | 1 |
| Linton, PH | 1 |
| Hanlon, TE | 2 |
| Schoenrich, C | 1 |
| Freinek, W | 1 |
| Turek, I | 1 |
| McLaughlin, BE | 1 |
| Kehoe, MJ | 1 |
| Czerniak, P | 1 |
| Haim, DB | 1 |
| Rafter, B | 1 |
| Henningsen, GJ | 1 |
| Michaux, MH | 1 |
| Ota, KY | 1 |
| Shaffer, JW | 1 |
| Radzuweit, H | 1 |
| Knorr, W | 1 |
| Gunby, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)[NCT00014001] | Phase 4 | 1,600 participants | Interventional | 2000-12-31 | Completed | ||
| Continuation Pharmacotherapy for Agitation of Dementia[NCT00073658] | Phase 2 | 137 participants | Interventional | 2000-01-31 | Completed | ||
| Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia[NCT00156715] | Phase 4 | 23 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)[NCT00130923] | Phase 4 | 95 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The main outcome measure of clinical symptoms was the Positive and Negative Symptoms Scale. This is a 30 item scale for assessing patients diagnosed with schizophrenia. Each item is rated on a 1 (absent) to 7 (extreme) scale. The minimum total score is 30 and the maximum is 210. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| QUET | 65.5 |
Timeline Follow-back (TLFB) procedure was used at screening and baseline to establish current substance use, and it was also used weekly during the course of the study to assess continued alcohol and other substance use. TLFB cosisted of using a calendar and sasking participants to report alcohol and other drug use since last visit. At the screening visit, the TLFB was done for the four weeks prior to the visit. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Drinking Days per Week (Mean) |
|---|---|
| QUET | 2.7 |
Frequency of drinking days is obtained each week retrospectively as the number of drinking days during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 2.84 |
| Oral Risperidone Aka Risperdal | 3.46 |
A rater assesses social, occupational and psychological functioning on a hypothetical continuum of mental health - illness (using Global Assessment of Functioning); scores range from 100 to 1, where higher values represent a better outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of impairment (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 50.8 |
| Oral Risperidone Aka Risperdal | 49.9 |
A rater assesses positive and negative symptoms of schizophrenia using a 30-item scale (Positive and Negative Symptom Score) Scores range from 30 to 210, where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of symptoms (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 78.2 |
| Oral Risperidone Aka Risperdal | 75.5 |
A rater assesses the severity of illness and global impression using a scale from 1 to 7 (Clinical Global Impression), where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal unit of severity (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 4.02 |
| Oral Risperidone Aka Risperal | 3.96 |
Frequency of heavy drinking days is obtained each week retrospectively as the number of heavy drinking days during the prior week (assessed by the Timeline Followback Scale). A heavy drinking day is defined as 4 or more drinks per day for a female and 5 or more drinks per day for a male. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | heavy drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | -.11 |
| Oral Risperidone Aka Risperal | .68 |
Number of participants with medication adherence (defined as taking medication at least 75% of the days in the treatment period). (NCT00130923)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 43 |
| Oral Risperidone Aka Risperdal | 28 |
3 reviews available for perphenazine and Psychoses
| Article | Year |
|---|---|
[Pharmacological treatment of delusional depression].
Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Delusions; Depressive Disorde | 1996 |
Perphenazine serum levels in patients on standard doses.
Topics: Humans; Perphenazine; Psychotic Disorders | 1989 |
II. Major tranquilizers.
Topics: Animals; Chemical and Drug Induced Liver Injury; Chlordiazepoxide; Chlorpromazine; Fluphenazine; Hem | 1971 |
21 trials available for perphenazine and Psychoses
| Article | Year |
|---|---|
Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.
Topics: Adult; Alcoholism; Antipsychotic Agents; Comorbidity; Female; Hospitalization; Humans; Male; Olanzap | 2020 |
Examination of heterogeneity in treatment response to antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Deprescriptions; Female; Humans; Kaplan-Meier Estimate; Male; Medicatio | 2019 |
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.
Topics: Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition Disorders; Fe | 2009 |
Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Awareness; Benzodiazepines; Case-Control Studies; C | 2012 |
Prolactin response to neuroleptic challenge in late-life psychosis.
Topics: Aged; Aged, 80 and over; Biomarkers; Female; Humans; Male; Perphenazine; Prolactin; Psychotic Disord | 1995 |
Recent life stressors and biological markers in newly admitted psychotic patients.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Biomarkers; Female; Homovanillic Acid; Human | 1997 |
The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT.
Topics: Age Distribution; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Antipsychotic Agents; D | 1998 |
Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Child; Cholinergic Antagonist | 1999 |
Fluvoxamine for psychosis in Alzheimer's disease.
Topics: Acute Disease; Aged; Alzheimer Disease; Ambulatory Care; Antipsychotic Agents; Brief Psychiatric Rat | 2001 |
Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Behavioral Symptoms; Citalopram; Dementia; Donepezil; | 2002 |
Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Dibenzoxazepines; | 1978 |
Clozapine versus perphenazine: the value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity.
Topics: Adult; Clozapine; Dibenzazepines; Dopamine; Female; Homovanillic Acid; Humans; Hypnotics and Sedativ | 1976 |
The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects.
Topics: Adult; Akathisia, Drug-Induced; Basal Ganglia Diseases; Benztropine; Clinical Trials as Topic; Dose- | 1990 |
[Results of treatment of schizophrenic and schizoaffective patients with sulpiride (Eglonyl Alkaloid) in comparison with perphenazine (Perfenazin Spofa)].
Topics: Adolescent; Adult; Humans; Middle Aged; Perphenazine; Psychotic Disorders; Schizophrenia; Sulpiride | 1990 |
Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Biperiden; Chlorprothixene; Dyskinesia, Drug-I | 1986 |
Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study.
Topics: Clopenthixol; Double-Blind Method; Humans; Nervous System Diseases; Perphenazine; Psychotic Disorder | 1987 |
The computer analyzes two psychotherapeutic agents in anxiety-depressed states.
Topics: Adolescent; Adult; Aged; Amitriptyline; Analysis of Variance; Anxiety; Chlorpromazine; Clinical Tria | 1973 |
Clinical experience with depot neuroleptics.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Drug Therapy, Combin | 1973 |
Perphenazine-benztropine mesylate treatment of newly admitted psychiatric patients.
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Synergism; Extrapyramidal Tracts; Female; Hospital | 1966 |
Therapy for psychotic and psychoneurotic depression with thiothixene and perphenazine-amitriptyline (a double-blind clinical study).
Topics: Amitriptyline; Clinical Trials as Topic; Depression; Drug Synergism; Factor Analysis, Statistical; H | 1969 |
The comparative effectiveness of eight phenothiazines.
Topics: Adolescent; Adult; Chlorpromazine; Clinical Trials as Topic; Female; Fluphenazine; Humans; Male; Mid | 1965 |
79 other studies available for perphenazine and Psychoses
| Article | Year |
|---|---|
Higher serum concentrations of tyrosine and glutamate in schizophrenia patients treated with clozapine, compared to in those treated with conventional antipsychotics.
Topics: Adult; Amino Acids; Antipsychotic Agents; Chromatography, Ion Exchange; Clopenthixol; Clozapine; Coh | 2015 |
Schizophrenia: The drug deadlock.
Topics: Animals; Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Cognition; Dopamine D2 Receptor | 2010 |
Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Chi-Square Distribution; Clopenthixo | 2009 |
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Female; Haloperido | 2011 |
The treatment of anxiety, agitation and excitement in the aged; a preliminary report on trilafon.
Topics: Aged; Anxiety; Dementia; Humans; Mental Disorders; Perphenazine; Psychomotor Agitation; Psychotic Di | 1957 |
Perphenazine; observations on the clinical effects of a new tranquillizing agent in psychotic conditions.
Topics: Perphenazine; Phenothiazines; Psychotic Disorders; Tranquilizing Agents | 1957 |
Perphenazine (trilafon) treatment of psychoses.
Topics: Mental Disorders; Perphenazine; Phenothiazines; Psychotic Disorders | 1957 |
[Pharmacotherapy of neuropsychiatric diseases with trilafon].
Topics: Perphenazine; Phenothiazines; Psychosurgery; Psychotic Disorders | 1958 |
[First results of perphenazine therapy in severe psychoses].
Topics: Electroconvulsive Therapy; Humans; Mental Disorders; Perphenazine; Psychosurgery; Psychotic Disorder | 1958 |
Trilafon treatment in psychotics.
Topics: Mental Disorders; Perphenazine; Phenothiazines; Psychotic Disorders | 1958 |
[Perphenazine treatment of psychoses].
Topics: Humans; Mental Disorders; Perphenazine; Phenothiazines; Psychotic Disorders | 1958 |
[Trilafon (perfenazin) & largactil (chlorpromazine) in chronic mental diseases; a comparison].
Topics: Chlorpromazine; Mental Disorders; Perphenazine; Phenothiazines; Psychotic Disorders | 1958 |
[Trilafon & states of excitement in aged psychotics].
Topics: Dementia; Humans; Mental Disorders; Perphenazine; Phenothiazines; Psychotic Disorders | 1958 |
Trilafon in the treatment of chronically psychotic hospitalized patients.
Topics: Mental Disorders; Perphenazine; Phenothiazines; Psychotic Disorders | 1958 |
Use of perphenazine in 100 hospitalized patients.
Topics: Perphenazine; Phenothiazines; Psychosurgery; Psychotic Disorders | 1958 |
Experience with reserpine (serpasil) and perphenazine (trilafon) in acute alcoholic intoxications and alcoholic psychosis.
Topics: Alcoholic Intoxication; Alcoholism; Humans; Perphenazine; Phenothiazines; Psychoses, Alcoholic; Psyc | 1958 |
[Preliminary note on the use of perphenazine (trilafon Schering) in severe psychoses].
Topics: Mental Disorders; Perphenazine; Phenothiazines; Psychotic Disorders | 1958 |
The phrenotropic action of trilafon (perphenazine) in 323 neuropsychiatric patients.
Topics: Humans; Neurotic Disorders; Perphenazine; Phenothiazines; Psychotherapy; Psychotic Disorders | 1959 |
[Treatment of endogenous psychoses with perphenazine (decentan)].
Topics: Mental Disorders; Perphenazine; Phenothiazines; Psychotic Disorders | 1959 |
[Results of treatment with perphenazine in schizophrenic psychoses with reference to extrapyramidal symptomatology].
Topics: Extrapyramidal Tracts; Mental Disorders; Perphenazine; Psychotic Disorders; Schizophrenia | 1961 |
[Clinical problems of chlorperphenazine therapy of psychoses].
Topics: Electroconvulsive Therapy; Mental Disorders; Perphenazine; Psychosurgery; Psychotic Disorders | 1960 |
[The treatment of endogenous depression with perphenazine and trihexyphenidyl. Relation to extrapyramidal symptomatology].
Topics: Bipolar Disorder; Depression; Depressive Disorder; Extrapyramidal Tracts; Humans; Mental Disorders; | 1962 |
Protein-bound iodine in patients receiving perphenazine.
Topics: Humans; Iodine; Mental Disorders; Perphenazine; Psychotic Disorders; Schizophrenia; Thyroid Function | 1963 |
[The use of neuroleptics in psychiatric and general practice].
Topics: Antipsychotic Agents; Chlorpromazine; Chlorprothixene; General Practice; Humans; Mental Disorders; P | 1963 |
Maintenance therapy of chronic psychotics with perphenazine.
Topics: Chronic Disease; Humans; Mental Disorders; Perphenazine; Psychotic Disorders | 1963 |
[A neuroleptic derivative of phenothiazine: perphenazine].
Topics: Alcoholism; Antipsychotic Agents; Character; Delusions; Dementia; Humans; Perphenazine; Phenothiazin | 1963 |
[Perphenazine, piperazine phenothiazine in psychiatric therapy].
Topics: Depression; Humans; Mental Disorders; Neurologic Manifestations; Neurotic Disorders; Perphenazine; P | 1963 |
[Trilafon in manic syndromes].
Topics: Bipolar Disorder; Mental Disorders; Perphenazine; Psychopharmacology; Psychotic Disorders; Syndrome | 1961 |
Evaluation of perphenazine in the treatment of Haitian psychotics.
Topics: Black or African American; Humans; Mental Disorders; Perphenazine; Psychotic Disorders | 1963 |
[TREATMENT OF MANIC PATIENTS WITH CHLORPROTHIXENE (TRUXAL) IN COMPARISON WITH OTHER TREATMENT METHODS, WITH SPECIAL REFERENCE TO THE DURATION OF STABILIZATION].
Topics: Amobarbital; Antipsychotic Agents; Bipolar Disorder; Chlorpromazine; Chlorprothixene; Convulsive The | 1963 |
PROLONGED PERPHENAZINE THERAPY AND THYROID FUNCTION.
Topics: Mental Disorders; Perphenazine; Pharmacology; Psychotic Disorders; Thyroid Function Tests; Thyroid G | 1963 |
THE REPETITIVE ADMINISTRATION OF TWO PSYCHOLOGICAL TESTS DURING WITHDRAWAL FROM ATARACTIC DRUGS.
Topics: Chlorpromazine; Humans; Mental Disorders; Perphenazine; Pharmaceutical Preparations; Prochlorperazin | 1963 |
SYMPTOM SPECIFICITY OF ANTI-PSYCHOTIC DRUGS.
Topics: Chlorpromazine; Humans; Mental Disorders; Perphenazine; Psychopharmacology; Psychotic Disorders; Sch | 1964 |
DRUG MAINTENANCE PROBLEMS OF REHABILITATED MENTAL PATIENTS: THE CURRENT DRUG DOSAGE "MERRY-GO-ROUND".
Topics: Chlordiazepoxide; Chlorpromazine; Depression; Imipramine; Mental Disorders; Mentally Ill Persons; Pe | 1964 |
PERPHENAZINE (TRILAFON) METABOLISM IN PSYCHOTIC PATIENTS.
Topics: Chlorpromazine; Chromatography; Humans; Mental Disorders; Metabolism; Perphenazine; Psychotic Disord | 1964 |
[DYNAMIC STUDIES ON DRAWING IN THE COURSE OF TREATMENT WITH PSYCHOTROPIC AGENTS].
Topics: Antisocial Personality Disorder; Bipolar Disorder; Depressive Disorder, Major; Imipramine; Mental Di | 1964 |
CHANGES IN SERUM PROTEINS AND CEREBROSPINAL FLUID PROTEINS DURING PHARMACOTHERAPY OF PSYCHOSES.
Topics: Alcoholism; Bipolar Disorder; Blood Proteins; Cerebrospinal Fluid Proteins; Chlorpromazine; Drug The | 1964 |
COMBINED PERPHENAZINE-AMITRIPTYLINE AS ADJUVANT THERAPY IN PSYCHIATRIC AFTERCARE.
Topics: Aftercare; Amitriptyline; Depression; Depressive Disorder; Drug Combinations; Drug Therapy; Humans; | 1964 |
A LONG-TERM STUDY OF 12 HOSPITALIZED PSYCHIATRIC PATIENTS TREATED WITH PERPHENAZINE.
Topics: Drug Therapy; Geriatrics; Humans; Longitudinal Studies; Mental Disorders; Paresis; Perphenazine; Psy | 1965 |
PENTOTHAL INDUCED CHANGES IN EEG AS A PROGNOSTIC INDEX IN DRUGS THERAPY OF PSYCHOTIC PATIENTS.
Topics: Chlorpromazine; Depression; Drug Therapy; Electroencephalography; Mental Disorders; Neurotic Disorde | 1965 |
COMPUTER ANALYSIS OF DRUG EFFECTS ON THE ELECTROENCEPHALOGRAMS OF NORMAL AND PSYCHOTIC SUBJECTS.
Topics: Antidepressive Agents; Biomedical Research; Chlorpromazine; Computers; Drug Therapy; Electroencephal | 1964 |
Nine months' treatment with trilafon (perphenazin) in a mental hospital.
Topics: Electroconvulsive Therapy; Hospitals, Psychiatric; Perphenazine; Psychosurgery; Psychotherapy; Psych | 1959 |
Did CATIE influence antipsychotic use?
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Therapy; Haloperidol; Hum | 2008 |
Abscesses following prolonged intramuscular administration of perphenazine enantate.
Topics: Abscess; Adult; Antipsychotic Agents; Humans; Injections, Intramuscular; Male; Middle Aged; Perphena | 1980 |
Metabolic interaction between perphenazine and disulfiram.
Topics: Adult; Alcoholism; Disulfiram; Drug Interactions; Humans; Male; Perphenazine; Psychotic Disorders | 1982 |
[Ataractic treatment in psychiatry and general medicine. Overview of preparations, 2].
Topics: Bromazepam; Carbamazepine; Chlordiazepoxide; Chlorpromazine; Humans; Perphenazine; Psychophysiologic | 1983 |
Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Female; Humans; Male; Middle Aged; Perphenazine; Prolacti | 1981 |
Dose-response relationships of perphenazine in the treatment of acute psychoses.
Topics: Acute Disease; Adolescent; Adult; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Female; | 1982 |
Low dose perphenazine and levodopa/carbidopa therapy in a patient with Parkinsonism and a psychotic illness.
Topics: Carbidopa; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Levodopa; Male; Midd | 1980 |
Quantitative determination of perphenazine and its metabolites in plasma by high-performance liquid chromatography and coulometric detection.
Topics: Aged; Antipsychotic Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Electrochemistry; | 1995 |
Treatment of resistant akathisia with ECT--a case report.
Topics: Akathisia, Drug-Induced; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electroconvuls | 1993 |
Use of risperidone in psychotic disorder following ischemic brain damage.
Topics: Adult; Brain Ischemia; Haloperidol; Humans; Male; Perphenazine; Psychotic Disorders; Risperidone | 1996 |
Neurological motor disorders experienced as religious phenomena: role of abnormal movement monitoring.
Topics: Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Perphenazine; Psychomotor Diso | 1998 |
Acute neuroleptic treatment in elderly patients without dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Chromatography, High Pressure Liquid; Dose-Response R | 1998 |
Adding other antipsychotics to clozapine.
Topics: Acute Disease; Antipsychotic Agents; Clozapine; Drug Administration Schedule; Drug Interactions; Dru | 1999 |
Fluvoxamine and perphenazine for psychosis in Alzheimer's disease: pharmacokinetic considerations.
Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactio | 2001 |
High-dosage and versatile drug therapy with treatment-resistant psychotic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Doxepin; Female; Hospitals, Psychiatric; Hu | 1976 |
Withdrawal psychosis: a study of 30 consecutive cases.
Topics: Adult; Aged; Analgesics; Antipsychotic Agents; Barbiturates; Benzodiazepines; Codeine; Female; Human | 1976 |
Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment.
Topics: Administration, Oral; Adult; Female; Humans; Male; Middle Aged; Perphenazine; Psychotic Disorders; S | 1977 |
Seven cases of somnambulism induced by drugs.
Topics: Adult; Alcoholism; Amitriptyline; Chlorprothixene; Depression; Drug Therapy, Combination; Ethchlorvy | 1979 |
Drug-induced dystonia.
Topics: Adjustment Disorders; Adult; Basal Ganglia Diseases; Chlorpromazine; Chlorprothixene; Female; Fluphe | 1975 |
Clinical treatment of post partum delirium with perfenazine and lithium carbonate.
Topics: Drug Evaluation; Drug Therapy, Combination; Female; Humans; Lithium; Perphenazine; Pregnancy; Psycho | 1975 |
Lithium in combination with perphenazine: effect on plasma monoamine metabolites.
Topics: Adult; Aged; Bipolar Disorder; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Lithium | 1992 |
Cycloid psychosis: regional cerebral blood flow correlates of a psychotic episode.
Topics: Adult; Aged; Bipolar Disorder; Blood Flow Velocity; Cerebral Cortex; Chlorpromazine; Dominance, Cere | 1992 |
Drug-responsive symptoms during early neuroleptic treatment.
Topics: Adult; Benztropine; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Drug Th | 1992 |
Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis.
Topics: Acute Disease; Adolescent; Adult; Bipolar Disorder; Chromatography, High Pressure Liquid; Depressive | 1991 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Perphenazine in breast milk and serum.
Topics: Adult; Breast Feeding; Chromatography, High Pressure Liquid; Circadian Rhythm; Female; Humans; Infan | 1990 |
Alprazolam for psychotic depression.
Topics: Adult; Alprazolam; Amitriptyline; Depressive Disorder; Female; Humans; Male; Perphenazine; Psycholog | 1989 |
Plasma catecholamine metabolites and treatment response at neuroleptic steady state.
Topics: Adolescent; Adult; Aged; Female; Glycols; Haloperidol; Homovanillic Acid; Humans; Male; Methoxyhydro | 1989 |
Neuroleptic malignant syndrome during perphenazine treatment.
Topics: Acute Kidney Injury; Creatine Kinase; Female; Humans; Middle Aged; Myoglobinuria; Neuroleptic Malign | 1987 |
Neuroleptic therapy following neuroleptic malignant syndrome.
Topics: Adult; Drug Therapy, Combination; Haloperidol; Humans; Male; Neuroleptic Malignant Syndrome; Perphen | 1985 |
Comparison of conventional neuroleptic therapy with depot neuroleptics. An attempt at economic evaluation.
Topics: Adult; Age Factors; Aged; Costs and Cost Analysis; Delayed-Action Preparations; Economics; Female; H | 1973 |
Use of perphenazine in psychiatric emergencies: the concept of chemical restraint.
Topics: Adult; Aggression; Emergencies; Hostility; Humans; Male; Perphenazine; Psychotic Disorders | 1972 |
Phenothiazine derivatives and brain zinc. Turnover radioactive isotope study.
Topics: Animals; Basal Ganglia; Brain; Cerebellum; Chlorpromazine; Frontal Lobe; Hippocampus; Humans; Limbic | 1971 |
[Clinical experiences with perphenazine enanthate].
Topics: Adolescent; Adult; Aged; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Mal | 1971 |
[Transvestism as a psychotic symptom in a 9-year-old girl].
Topics: Body Image; Child; Chlorprothixene; Female; Humans; Perphenazine; Psychological Tests; Psychotherapy | 1971 |
[Influencing of biological and immunologic pregnancy reactions by psychotropic drugs].
Topics: Adolescent; Adult; Aged; Butyrophenones; Chlorpromazine; Dementia; Depressive Disorder, Major; Dysau | 1969 |
[Perphenazine enantate in long-term therapy of psychoses].
Topics: Adult; Aged; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Perphenazine; Psychotic D | 1968 |